智通财经APP获悉，百济神州(06160)涨超8%，截至发稿，涨8.17%，报174.8港元，成交额2.1亿港元。
消息面上，百济神州公布2024年第四季度和全年财务业绩，2024年第四季度，公司全球总收入达11.28亿美元，同比增长78%，经调整经营利润7860.3万美元，同比扭亏为盈；2024年全年，公司全球总收入达38.1亿美元，同比增长55%；经调整经营利润4535.6万美元，同比扭亏为盈；GAAP经营亏损持续收窄，实现全年非GAAP经营利润为正。
百悦泽®第四季度全球销售额达8.28亿美元，同比增长100%，全年全球销售额达26亿美元，同比增长105%；BCL2抑制剂sonrotoclax和BTK CDAC BGB-16673已推进至关键性项目阶段。第四季度推动6款新分子实体（NME）进入临床开发阶段，全年共有13款；预计2025年上半年将有多个创新性实体瘤项目进行数据读出公司2025年全年收入指引为49亿至53亿美元，同时重申预计GAAP经营利润为正且经营活动产生现金流为正。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.